1. Home
  2. BCAB vs MAIA Comparison

BCAB vs MAIA Comparison

Compare BCAB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • MAIA
  • Stock Information
  • Founded
  • BCAB 2007
  • MAIA 2018
  • Country
  • BCAB United States
  • MAIA United States
  • Employees
  • BCAB N/A
  • MAIA N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • MAIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCAB Health Care
  • MAIA Health Care
  • Exchange
  • BCAB Nasdaq
  • MAIA Nasdaq
  • Market Cap
  • BCAB 96.2M
  • MAIA 62.4M
  • IPO Year
  • BCAB 2020
  • MAIA 2022
  • Fundamental
  • Price
  • BCAB $2.08
  • MAIA $2.82
  • Analyst Decision
  • BCAB Strong Buy
  • MAIA
  • Analyst Count
  • BCAB 2
  • MAIA 0
  • Target Price
  • BCAB $6.00
  • MAIA N/A
  • AVG Volume (30 Days)
  • BCAB 1.6M
  • MAIA 60.0K
  • Earning Date
  • BCAB 11-08-2024
  • MAIA 11-05-2024
  • Dividend Yield
  • BCAB N/A
  • MAIA N/A
  • EPS Growth
  • BCAB N/A
  • MAIA N/A
  • EPS
  • BCAB N/A
  • MAIA N/A
  • Revenue
  • BCAB N/A
  • MAIA N/A
  • Revenue This Year
  • BCAB N/A
  • MAIA N/A
  • Revenue Next Year
  • BCAB N/A
  • MAIA N/A
  • P/E Ratio
  • BCAB N/A
  • MAIA N/A
  • Revenue Growth
  • BCAB N/A
  • MAIA N/A
  • 52 Week Low
  • BCAB $1.14
  • MAIA $0.82
  • 52 Week High
  • BCAB $4.02
  • MAIA $5.99
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.80
  • MAIA 50.98
  • Support Level
  • BCAB $1.87
  • MAIA $2.36
  • Resistance Level
  • BCAB $2.13
  • MAIA $2.72
  • Average True Range (ATR)
  • BCAB 0.12
  • MAIA 0.22
  • MACD
  • BCAB 0.00
  • MAIA 0.02
  • Stochastic Oscillator
  • BCAB 68.90
  • MAIA 72.28

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Share on Social Networks: